Post-earnings recap
Reported
Thu, May 7, 2026
EPS actual
$0.00
EPS est.
$-0.02
EPS surprise
+100.00%
1-day move
+3.71%
Caris Life Sciences reported an EPS of $0.00, which met expectations, resulting in a 3.71% increase in stock price. However, there was no revenue reported, and no guidance was provided for future performance. The stock reaction suggests that investors may have found the EPS result encouraging, despite the lack of additional financial details.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.00 | N/A | +100.00% |
| Revenue | — | N/A | — |
No transcript is on record, and the analysis is based solely on numerical results.
Caris Life Sciences, Inc. is a biotechnology company focused on precision medicine. They provide advanced genomic testing services that help healthcare providers make more informed treatment decisions. As part of the health care sector, their work is critical in the evolving landscape of personalized medicine.
Last quarter
In the last quarter, Caris Life Sciences reported a significant EPS surprise of $0.28, far exceeding expectations. The stock reacted positively, gaining 5.08% the next day.
EPS beat streak
4Q
EPS beat rate
88%
Avg EPS surprise
+547.12%
Avg 1-day reaction
+1.51%
Overall, expectations for Caris Life Sciences are mixed as the company has shown a strong ability to beat EPS estimates in the past. However, there is uncertainty regarding revenue figures and future guidance.
Bull case
The optimistic view is that Caris will continue its streak of beating EPS estimates, potentially leading to increased investor confidence and stock price appreciation.
Bear case
On the other hand, if Caris fails to meet expectations or provides weak guidance, it could lead to a decline in stock price, reflecting investor disappointment.
The print will turn on these.
Q1
What will be the EPS for Q1-2026?
Given Caris's history of beating EPS estimates, the market will closely watch this figure to gauge ongoing profitability.
Q2
What are the revenue figures for this quarter?
Revenue is crucial for understanding the company's growth trajectory and market position, especially in the competitive biotech space.
—
Est. EPS
$0.97
Est. Rev
$754M
Impl. Move
±9.1%
Why consensus could be wrong
The market may underestimate Caris's ability to leverage its genomic testing services for revenue growth, especially in light of recent advancements in precision medicine.
Supporting evidence
Caris has consistently beaten EPS estimates, indicating strong operational execution.
The options market is pricing in a larger move than historical averages, suggesting heightened expectations.
Recent trends in personalized medicine could drive demand for Caris's services beyond current projections.
Key risk
If revenue growth exceeds expectations, it could challenge the current cautious outlook.
Pre-commit to what would confirm each case.
This quarter's performance is critical as it will determine if Caris can maintain its momentum or if it will face challenges.
Bull confirmed if
An EPS of $0.30 or higher would confirm the bull case and indicate strong operational performance.
Bear confirmed if
An EPS below $0.01 would confirm the bear case and raise concerns about the company's profitability.
What the market is pricing for the move.
Implied Move
±12.66%
Historical Avg
±4.9%
The options market is pricing in a significant move, suggesting that investors expect volatility around the earnings announcement.
Options are pricing ±31.7% while CAI has averaged ±4.9% over the last 5 prints — setup is pricing rich.
ATM IV
3.3%
30d HV
63.9%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If Caris beats expectations, history suggests a potential stock increase of around 6.28%, confirming strong operational health.
In line / cautious
If results are in line with expectations, the stock may react cautiously, reflecting uncertainty in future growth.
Miss
A miss could lead to a decline, with historical patterns suggesting a potential drop of around 6.32%.
The lines on the call that would change the story.